Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Grignani

Showing results (591-600 of 688) with videos related to

Pageof 69
Sort By:
Therapeutic Advances in Medical Oncology|February 17, 2018
Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practiceMargherita Nannini, Maria Concetta Nigro, Bruno Vincenzi, et al.
Haematologica|September 22, 2011
Clinical and laboratory features of 103 patients from 42 Italian families with inherited thrombocytopenia derived from the monoallelic Ala156Val mutation of GPIbα (Bolzano mutation)Patrizia Noris, Silverio Perrotta, Roberta Bottega, et al.
European Journal of Cancer (Oxford, England : 1990)|October 2, 2014
Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumourS Stacchiotti, M Tortoreto, G G Baldi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 9, 2020
CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma HistotypesValeria Leuci, Chiara Donini, Giovanni Grignani, et al.
Cancer|November 14, 2024
Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single-arm, phase 2 trialEmanuela Palmerini, Antonio Lopez Pousa, Giovanni Grignani, et al.
American Journal of Hematology|June 24, 2020
Genetic lesions disrupting calreticulin 3'-untranslated region in JAK2 mutation-negative polycythemia veraAlberto Quattrocchi, Carlo Maiorca, Monia Billi, et al.
Frontiers in Oncology|September 16, 2022
DNA damage response and repair genes in advanced bone and soft tissue sarcomas: An 8-gene signature as a candidate predictive biomarker of response to trabectedin and olaparib combinationAlessandra Merlini, Maria Laura Centomo, Giulio Ferrero, et al.
Frontiers in Oncology|January 21, 2022
<i>SDHA</i> Germline Variants in Adult Patients With <i>SDHA</i>-Mutant Gastrointestinal Stromal TumorMaria A Pantaleo, Milena Urbini, Angela Schipani, et al.
Recenti Progressi in Medicina|December 9, 1998
[Assessment of clinical competence of medical school graduates in Italy with standardized patients. The opinion of the examinees]S Sensi, M F Ben-David, M T Guagnano, et al.
The Lancet. Oncology|September 16, 2018
Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma GroupGiovanni Grignani, Lorenzo D'Ambrosio, Ymera Pignochino, et al.
Pageof 69

Showing results (591-600 of 688) with videos related to

Sort By:
Pageof 69
Therapeutic Advances in Medical Oncology|February 17, 2018
Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practiceMargherita Nannini, Maria Concetta Nigro, Bruno Vincenzi, et al.
Haematologica|September 22, 2011
Clinical and laboratory features of 103 patients from 42 Italian families with inherited thrombocytopenia derived from the monoallelic Ala156Val mutation of GPIbα (Bolzano mutation)Patrizia Noris, Silverio Perrotta, Roberta Bottega, et al.
European Journal of Cancer (Oxford, England : 1990)|October 2, 2014
Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumourS Stacchiotti, M Tortoreto, G G Baldi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 9, 2020
CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma HistotypesValeria Leuci, Chiara Donini, Giovanni Grignani, et al.
Cancer|November 14, 2024
Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single-arm, phase 2 trialEmanuela Palmerini, Antonio Lopez Pousa, Giovanni Grignani, et al.
American Journal of Hematology|June 24, 2020
Genetic lesions disrupting calreticulin 3'-untranslated region in JAK2 mutation-negative polycythemia veraAlberto Quattrocchi, Carlo Maiorca, Monia Billi, et al.
Frontiers in Oncology|September 16, 2022
DNA damage response and repair genes in advanced bone and soft tissue sarcomas: An 8-gene signature as a candidate predictive biomarker of response to trabectedin and olaparib combinationAlessandra Merlini, Maria Laura Centomo, Giulio Ferrero, et al.
Frontiers in Oncology|January 21, 2022
<i>SDHA</i> Germline Variants in Adult Patients With <i>SDHA</i>-Mutant Gastrointestinal Stromal TumorMaria A Pantaleo, Milena Urbini, Angela Schipani, et al.
Recenti Progressi in Medicina|December 9, 1998
[Assessment of clinical competence of medical school graduates in Italy with standardized patients. The opinion of the examinees]S Sensi, M F Ben-David, M T Guagnano, et al.
The Lancet. Oncology|September 16, 2018
Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma GroupGiovanni Grignani, Lorenzo D'Ambrosio, Ymera Pignochino, et al.
Pageof 69